nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—Angiopathy—Vincristine—colon cancer	0.00359	0.00359	CcSEcCtD
Rifaximin—Flushing—Irinotecan—colon cancer	0.00357	0.00357	CcSEcCtD
Rifaximin—Mediastinal disorder—Vincristine—colon cancer	0.00356	0.00356	CcSEcCtD
Rifaximin—Angiopathy—Irinotecan—colon cancer	0.00349	0.00349	CcSEcCtD
Rifaximin—Mediastinal disorder—Irinotecan—colon cancer	0.00347	0.00347	CcSEcCtD
Rifaximin—Dehydration—Capecitabine—colon cancer	0.00346	0.00346	CcSEcCtD
Rifaximin—Mental disorder—Vincristine—colon cancer	0.00346	0.00346	CcSEcCtD
Rifaximin—Urine output increased—Methotrexate—colon cancer	0.00345	0.00345	CcSEcCtD
Rifaximin—Abdominal pain upper—Capecitabine—colon cancer	0.0034	0.0034	CcSEcCtD
Rifaximin—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.00335	0.00335	CcSEcCtD
Rifaximin—Nasopharyngitis—Capecitabine—colon cancer	0.00333	0.00333	CcSEcCtD
Rifaximin—Back pain—Vincristine—colon cancer	0.00333	0.00333	CcSEcCtD
Rifaximin—Flatulence—Irinotecan—colon cancer	0.0033	0.0033	CcSEcCtD
Rifaximin—Back pain—Irinotecan—colon cancer	0.00324	0.00324	CcSEcCtD
Rifaximin—Abdominal distension—Capecitabine—colon cancer	0.00324	0.00324	CcSEcCtD
Rifaximin—Muscle spasms—Irinotecan—colon cancer	0.00322	0.00322	CcSEcCtD
Rifaximin—Dysphagia—Capecitabine—colon cancer	0.00322	0.00322	CcSEcCtD
Rifaximin—Anaemia—Vincristine—colon cancer	0.00318	0.00318	CcSEcCtD
Rifaximin—Polyuria—Methotrexate—colon cancer	0.00316	0.00316	CcSEcCtD
Rifaximin—Sweating increased—Capecitabine—colon cancer	0.00314	0.00314	CcSEcCtD
Rifaximin—Ill-defined disorder—Irinotecan—colon cancer	0.00311	0.00311	CcSEcCtD
Rifaximin—Anaemia—Irinotecan—colon cancer	0.0031	0.0031	CcSEcCtD
Rifaximin—Vertigo—Vincristine—colon cancer	0.00309	0.00309	CcSEcCtD
Rifaximin—Abdominal discomfort—Capecitabine—colon cancer	0.00309	0.00309	CcSEcCtD
Rifaximin—Malaise—Irinotecan—colon cancer	0.00302	0.00302	CcSEcCtD
Rifaximin—Vertigo—Irinotecan—colon cancer	0.00301	0.00301	CcSEcCtD
Rifaximin—Neutropenia—Capecitabine—colon cancer	0.00301	0.00301	CcSEcCtD
Rifaximin—Dysuria—Capecitabine—colon cancer	0.00301	0.00301	CcSEcCtD
Rifaximin—Syncope—Irinotecan—colon cancer	0.00301	0.00301	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Capecitabine—colon cancer	0.00299	0.00299	CcSEcCtD
Rifaximin—Anaemia—Fluorouracil—colon cancer	0.00297	0.00297	CcSEcCtD
Rifaximin—Loss of consciousness—Irinotecan—colon cancer	0.00295	0.00295	CcSEcCtD
Rifaximin—Dermatitis exfoliative—Methotrexate—colon cancer	0.00294	0.00294	CcSEcCtD
Rifaximin—Photosensitivity reaction—Capecitabine—colon cancer	0.00294	0.00294	CcSEcCtD
Rifaximin—Myalgia—Vincristine—colon cancer	0.00293	0.00293	CcSEcCtD
Rifaximin—Weight increased—Capecitabine—colon cancer	0.00293	0.00293	CcSEcCtD
Rifaximin—Cough—Irinotecan—colon cancer	0.00293	0.00293	CcSEcCtD
Rifaximin—Weight decreased—Capecitabine—colon cancer	0.00291	0.00291	CcSEcCtD
Rifaximin—Hyperglycaemia—Capecitabine—colon cancer	0.0029	0.0029	CcSEcCtD
Rifaximin—Pneumonia—Capecitabine—colon cancer	0.00289	0.00289	CcSEcCtD
Rifaximin—Infestation NOS—Capecitabine—colon cancer	0.00287	0.00287	CcSEcCtD
Rifaximin—Infestation—Capecitabine—colon cancer	0.00287	0.00287	CcSEcCtD
Rifaximin—Depression—Capecitabine—colon cancer	0.00286	0.00286	CcSEcCtD
Rifaximin—Discomfort—Irinotecan—colon cancer	0.00282	0.00282	CcSEcCtD
Rifaximin—Anaphylactic shock—Vincristine—colon cancer	0.00281	0.00281	CcSEcCtD
Rifaximin—Infection—Vincristine—colon cancer	0.00279	0.00279	CcSEcCtD
Rifaximin—Confusional state—Irinotecan—colon cancer	0.00276	0.00276	CcSEcCtD
Rifaximin—Nervous system disorder—Vincristine—colon cancer	0.00275	0.00275	CcSEcCtD
Rifaximin—Haematuria—Capecitabine—colon cancer	0.00274	0.00274	CcSEcCtD
Rifaximin—Anaphylactic shock—Irinotecan—colon cancer	0.00274	0.00274	CcSEcCtD
Rifaximin—Myalgia—Fluorouracil—colon cancer	0.00273	0.00273	CcSEcCtD
Rifaximin—Chest pain—Fluorouracil—colon cancer	0.00273	0.00273	CcSEcCtD
Rifaximin—Infection—Irinotecan—colon cancer	0.00272	0.00272	CcSEcCtD
Rifaximin—Hyperhidrosis—Vincristine—colon cancer	0.00272	0.00272	CcSEcCtD
Rifaximin—Epistaxis—Capecitabine—colon cancer	0.00271	0.00271	CcSEcCtD
Rifaximin—Discomfort—Fluorouracil—colon cancer	0.0027	0.0027	CcSEcCtD
Rifaximin—Shock—Irinotecan—colon cancer	0.00269	0.00269	CcSEcCtD
Rifaximin—Nervous system disorder—Irinotecan—colon cancer	0.00268	0.00268	CcSEcCtD
Rifaximin—Anorexia—Vincristine—colon cancer	0.00268	0.00268	CcSEcCtD
Rifaximin—Hyperhidrosis—Irinotecan—colon cancer	0.00264	0.00264	CcSEcCtD
Rifaximin—Confusional state—Fluorouracil—colon cancer	0.00264	0.00264	CcSEcCtD
Rifaximin—Hypotension—Vincristine—colon cancer	0.00262	0.00262	CcSEcCtD
Rifaximin—Anaphylactic shock—Fluorouracil—colon cancer	0.00262	0.00262	CcSEcCtD
Rifaximin—Anorexia—Irinotecan—colon cancer	0.00261	0.00261	CcSEcCtD
Rifaximin—Infection—Fluorouracil—colon cancer	0.0026	0.0026	CcSEcCtD
Rifaximin—Haemoglobin—Capecitabine—colon cancer	0.00259	0.00259	CcSEcCtD
Rifaximin—Rhinitis—Capecitabine—colon cancer	0.00258	0.00258	CcSEcCtD
Rifaximin—Haemorrhage—Capecitabine—colon cancer	0.00258	0.00258	CcSEcCtD
Rifaximin—Nervous system disorder—Fluorouracil—colon cancer	0.00257	0.00257	CcSEcCtD
Rifaximin—Hypoaesthesia—Capecitabine—colon cancer	0.00256	0.00256	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Vincristine—colon cancer	0.00256	0.00256	CcSEcCtD
Rifaximin—Pharyngitis—Capecitabine—colon cancer	0.00256	0.00256	CcSEcCtD
Rifaximin—Hypotension—Irinotecan—colon cancer	0.00256	0.00256	CcSEcCtD
Rifaximin—Urinary tract disorder—Capecitabine—colon cancer	0.00255	0.00255	CcSEcCtD
Rifaximin—Insomnia—Vincristine—colon cancer	0.00254	0.00254	CcSEcCtD
Rifaximin—Oedema peripheral—Capecitabine—colon cancer	0.00254	0.00254	CcSEcCtD
Rifaximin—Urethral disorder—Capecitabine—colon cancer	0.00253	0.00253	CcSEcCtD
Rifaximin—Anorexia—Fluorouracil—colon cancer	0.0025	0.0025	CcSEcCtD
Rifaximin—Insomnia—Irinotecan—colon cancer	0.00247	0.00247	CcSEcCtD
Rifaximin—Hypotension—Fluorouracil—colon cancer	0.00245	0.00245	CcSEcCtD
Rifaximin—Decreased appetite—Vincristine—colon cancer	0.00244	0.00244	CcSEcCtD
Rifaximin—Dyspnoea—Irinotecan—colon cancer	0.00244	0.00244	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Vincristine—colon cancer	0.00243	0.00243	CcSEcCtD
Rifaximin—Fatigue—Vincristine—colon cancer	0.00242	0.00242	CcSEcCtD
Rifaximin—Tinnitus—Capecitabine—colon cancer	0.0024	0.0024	CcSEcCtD
Rifaximin—Constipation—Vincristine—colon cancer	0.0024	0.0024	CcSEcCtD
Rifaximin—Pain—Vincristine—colon cancer	0.0024	0.0024	CcSEcCtD
Rifaximin—Flushing—Capecitabine—colon cancer	0.00239	0.00239	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00239	0.00239	CcSEcCtD
Rifaximin—Decreased appetite—Irinotecan—colon cancer	0.00238	0.00238	CcSEcCtD
Rifaximin—Insomnia—Fluorouracil—colon cancer	0.00237	0.00237	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Irinotecan—colon cancer	0.00236	0.00236	CcSEcCtD
Rifaximin—Fatigue—Irinotecan—colon cancer	0.00236	0.00236	CcSEcCtD
Rifaximin—Pain—Irinotecan—colon cancer	0.00234	0.00234	CcSEcCtD
Rifaximin—Constipation—Irinotecan—colon cancer	0.00234	0.00234	CcSEcCtD
Rifaximin—Angiopathy—Capecitabine—colon cancer	0.00234	0.00234	CcSEcCtD
Rifaximin—Dyspnoea—Fluorouracil—colon cancer	0.00234	0.00234	CcSEcCtD
Rifaximin—Mediastinal disorder—Capecitabine—colon cancer	0.00232	0.00232	CcSEcCtD
Rifaximin—Abdominal discomfort—Methotrexate—colon cancer	0.0023	0.0023	CcSEcCtD
Rifaximin—Gastrointestinal pain—Vincristine—colon cancer	0.0023	0.0023	CcSEcCtD
Rifaximin—Decreased appetite—Fluorouracil—colon cancer	0.00228	0.00228	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00226	0.00226	CcSEcCtD
Rifaximin—Mental disorder—Capecitabine—colon cancer	0.00226	0.00226	CcSEcCtD
Rifaximin—Feeling abnormal—Irinotecan—colon cancer	0.00225	0.00225	CcSEcCtD
Rifaximin—Malnutrition—Capecitabine—colon cancer	0.00224	0.00224	CcSEcCtD
Rifaximin—Neutropenia—Methotrexate—colon cancer	0.00224	0.00224	CcSEcCtD
Rifaximin—Dysuria—Methotrexate—colon cancer	0.00224	0.00224	CcSEcCtD
Rifaximin—Pain—Fluorouracil—colon cancer	0.00224	0.00224	CcSEcCtD
Rifaximin—Gastrointestinal pain—Irinotecan—colon cancer	0.00224	0.00224	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Methotrexate—colon cancer	0.00223	0.00223	CcSEcCtD
Rifaximin—Abdominal pain—Vincristine—colon cancer	0.00222	0.00222	CcSEcCtD
Rifaximin—Body temperature increased—Vincristine—colon cancer	0.00222	0.00222	CcSEcCtD
Rifaximin—Flatulence—Capecitabine—colon cancer	0.00221	0.00221	CcSEcCtD
Rifaximin—Photosensitivity reaction—Methotrexate—colon cancer	0.00219	0.00219	CcSEcCtD
Rifaximin—Back pain—Capecitabine—colon cancer	0.00217	0.00217	CcSEcCtD
Rifaximin—Abdominal pain—Irinotecan—colon cancer	0.00216	0.00216	CcSEcCtD
Rifaximin—Body temperature increased—Irinotecan—colon cancer	0.00216	0.00216	CcSEcCtD
Rifaximin—Feeling abnormal—Fluorouracil—colon cancer	0.00216	0.00216	CcSEcCtD
Rifaximin—Muscle spasms—Capecitabine—colon cancer	0.00216	0.00216	CcSEcCtD
Rifaximin—Pneumonia—Methotrexate—colon cancer	0.00215	0.00215	CcSEcCtD
Rifaximin—Infestation—Methotrexate—colon cancer	0.00214	0.00214	CcSEcCtD
Rifaximin—Infestation NOS—Methotrexate—colon cancer	0.00214	0.00214	CcSEcCtD
Rifaximin—Depression—Methotrexate—colon cancer	0.00213	0.00213	CcSEcCtD
Rifaximin—Tremor—Capecitabine—colon cancer	0.0021	0.0021	CcSEcCtD
Rifaximin—Ill-defined disorder—Capecitabine—colon cancer	0.00208	0.00208	CcSEcCtD
Rifaximin—Urticaria—Fluorouracil—colon cancer	0.00208	0.00208	CcSEcCtD
Rifaximin—Anaemia—Capecitabine—colon cancer	0.00207	0.00207	CcSEcCtD
Rifaximin—Body temperature increased—Fluorouracil—colon cancer	0.00207	0.00207	CcSEcCtD
Rifaximin—Hypersensitivity—Vincristine—colon cancer	0.00207	0.00207	CcSEcCtD
Rifaximin—Haematuria—Methotrexate—colon cancer	0.00204	0.00204	CcSEcCtD
Rifaximin—Malaise—Capecitabine—colon cancer	0.00202	0.00202	CcSEcCtD
Rifaximin—Epistaxis—Methotrexate—colon cancer	0.00202	0.00202	CcSEcCtD
Rifaximin—Vertigo—Capecitabine—colon cancer	0.00202	0.00202	CcSEcCtD
Rifaximin—Hypersensitivity—Irinotecan—colon cancer	0.00202	0.00202	CcSEcCtD
Rifaximin—Asthenia—Vincristine—colon cancer	0.00202	0.00202	CcSEcCtD
Rifaximin—Syncope—Capecitabine—colon cancer	0.00201	0.00201	CcSEcCtD
Rifaximin—Loss of consciousness—Capecitabine—colon cancer	0.00197	0.00197	CcSEcCtD
Rifaximin—Asthenia—Irinotecan—colon cancer	0.00196	0.00196	CcSEcCtD
Rifaximin—Cough—Capecitabine—colon cancer	0.00196	0.00196	CcSEcCtD
Rifaximin—Hypersensitivity—Fluorouracil—colon cancer	0.00193	0.00193	CcSEcCtD
Rifaximin—Haemoglobin—Methotrexate—colon cancer	0.00193	0.00193	CcSEcCtD
Rifaximin—Diarrhoea—Vincristine—colon cancer	0.00192	0.00192	CcSEcCtD
Rifaximin—Haemorrhage—Methotrexate—colon cancer	0.00192	0.00192	CcSEcCtD
Rifaximin—Chest pain—Capecitabine—colon cancer	0.00191	0.00191	CcSEcCtD
Rifaximin—Arthralgia—Capecitabine—colon cancer	0.00191	0.00191	CcSEcCtD
Rifaximin—Myalgia—Capecitabine—colon cancer	0.00191	0.00191	CcSEcCtD
Rifaximin—Pharyngitis—Methotrexate—colon cancer	0.0019	0.0019	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.0019	0.0019	CcSEcCtD
Rifaximin—Urinary tract disorder—Methotrexate—colon cancer	0.00189	0.00189	CcSEcCtD
Rifaximin—Discomfort—Capecitabine—colon cancer	0.00189	0.00189	CcSEcCtD
Rifaximin—Urethral disorder—Methotrexate—colon cancer	0.00188	0.00188	CcSEcCtD
Rifaximin—Diarrhoea—Irinotecan—colon cancer	0.00187	0.00187	CcSEcCtD
Rifaximin—Dry mouth—Capecitabine—colon cancer	0.00187	0.00187	CcSEcCtD
Rifaximin—Dizziness—Vincristine—colon cancer	0.00186	0.00186	CcSEcCtD
Rifaximin—Pruritus—Fluorouracil—colon cancer	0.00185	0.00185	CcSEcCtD
Rifaximin—Confusional state—Capecitabine—colon cancer	0.00185	0.00185	CcSEcCtD
Rifaximin—Infection—Capecitabine—colon cancer	0.00182	0.00182	CcSEcCtD
Rifaximin—Dizziness—Irinotecan—colon cancer	0.00181	0.00181	CcSEcCtD
Rifaximin—Shock—Capecitabine—colon cancer	0.0018	0.0018	CcSEcCtD
Rifaximin—Nervous system disorder—Capecitabine—colon cancer	0.0018	0.0018	CcSEcCtD
Rifaximin—Diarrhoea—Fluorouracil—colon cancer	0.00179	0.00179	CcSEcCtD
Rifaximin—Tinnitus—Methotrexate—colon cancer	0.00179	0.00179	CcSEcCtD
Rifaximin—Vomiting—Vincristine—colon cancer	0.00179	0.00179	CcSEcCtD
Rifaximin—Skin disorder—Capecitabine—colon cancer	0.00178	0.00178	CcSEcCtD
Rifaximin—Rash—Vincristine—colon cancer	0.00177	0.00177	CcSEcCtD
Rifaximin—Hyperhidrosis—Capecitabine—colon cancer	0.00177	0.00177	CcSEcCtD
Rifaximin—Dermatitis—Vincristine—colon cancer	0.00177	0.00177	CcSEcCtD
Rifaximin—Headache—Vincristine—colon cancer	0.00176	0.00176	CcSEcCtD
Rifaximin—Anorexia—Capecitabine—colon cancer	0.00175	0.00175	CcSEcCtD
Rifaximin—Angiopathy—Methotrexate—colon cancer	0.00174	0.00174	CcSEcCtD
Rifaximin—Vomiting—Irinotecan—colon cancer	0.00174	0.00174	CcSEcCtD
Rifaximin—Dizziness—Fluorouracil—colon cancer	0.00173	0.00173	CcSEcCtD
Rifaximin—Mediastinal disorder—Methotrexate—colon cancer	0.00173	0.00173	CcSEcCtD
Rifaximin—Rash—Irinotecan—colon cancer	0.00172	0.00172	CcSEcCtD
Rifaximin—Dermatitis—Irinotecan—colon cancer	0.00172	0.00172	CcSEcCtD
Rifaximin—Headache—Irinotecan—colon cancer	0.00171	0.00171	CcSEcCtD
Rifaximin—Hypotension—Capecitabine—colon cancer	0.00171	0.00171	CcSEcCtD
Rifaximin—Mental disorder—Methotrexate—colon cancer	0.00168	0.00168	CcSEcCtD
Rifaximin—Malnutrition—Methotrexate—colon cancer	0.00167	0.00167	CcSEcCtD
Rifaximin—Nausea—Vincristine—colon cancer	0.00167	0.00167	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00167	0.00167	CcSEcCtD
Rifaximin—Vomiting—Fluorouracil—colon cancer	0.00167	0.00167	CcSEcCtD
Rifaximin—Insomnia—Capecitabine—colon cancer	0.00166	0.00166	CcSEcCtD
Rifaximin—Rash—Fluorouracil—colon cancer	0.00165	0.00165	CcSEcCtD
Rifaximin—Dermatitis—Fluorouracil—colon cancer	0.00165	0.00165	CcSEcCtD
Rifaximin—Headache—Fluorouracil—colon cancer	0.00164	0.00164	CcSEcCtD
Rifaximin—Dyspnoea—Capecitabine—colon cancer	0.00163	0.00163	CcSEcCtD
Rifaximin—Nausea—Irinotecan—colon cancer	0.00162	0.00162	CcSEcCtD
Rifaximin—Back pain—Methotrexate—colon cancer	0.00162	0.00162	CcSEcCtD
Rifaximin—Decreased appetite—Capecitabine—colon cancer	0.00159	0.00159	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Capecitabine—colon cancer	0.00158	0.00158	CcSEcCtD
Rifaximin—Fatigue—Capecitabine—colon cancer	0.00158	0.00158	CcSEcCtD
Rifaximin—Pain—Capecitabine—colon cancer	0.00157	0.00157	CcSEcCtD
Rifaximin—Constipation—Capecitabine—colon cancer	0.00157	0.00157	CcSEcCtD
Rifaximin—Nausea—Fluorouracil—colon cancer	0.00156	0.00156	CcSEcCtD
Rifaximin—Ill-defined disorder—Methotrexate—colon cancer	0.00155	0.00155	CcSEcCtD
Rifaximin—Anaemia—Methotrexate—colon cancer	0.00154	0.00154	CcSEcCtD
Rifaximin—Feeling abnormal—Capecitabine—colon cancer	0.00151	0.00151	CcSEcCtD
Rifaximin—Malaise—Methotrexate—colon cancer	0.00151	0.00151	CcSEcCtD
Rifaximin—Vertigo—Methotrexate—colon cancer	0.0015	0.0015	CcSEcCtD
Rifaximin—Gastrointestinal pain—Capecitabine—colon cancer	0.0015	0.0015	CcSEcCtD
Rifaximin—Cough—Methotrexate—colon cancer	0.00146	0.00146	CcSEcCtD
Rifaximin—Urticaria—Capecitabine—colon cancer	0.00145	0.00145	CcSEcCtD
Rifaximin—Abdominal pain—Capecitabine—colon cancer	0.00145	0.00145	CcSEcCtD
Rifaximin—Body temperature increased—Capecitabine—colon cancer	0.00145	0.00145	CcSEcCtD
Rifaximin—Arthralgia—Methotrexate—colon cancer	0.00142	0.00142	CcSEcCtD
Rifaximin—Chest pain—Methotrexate—colon cancer	0.00142	0.00142	CcSEcCtD
Rifaximin—Myalgia—Methotrexate—colon cancer	0.00142	0.00142	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00141	0.00141	CcSEcCtD
Rifaximin—Discomfort—Methotrexate—colon cancer	0.0014	0.0014	CcSEcCtD
Rifaximin—Confusional state—Methotrexate—colon cancer	0.00137	0.00137	CcSEcCtD
Rifaximin—Anaphylactic shock—Methotrexate—colon cancer	0.00136	0.00136	CcSEcCtD
Rifaximin—Infection—Methotrexate—colon cancer	0.00135	0.00135	CcSEcCtD
Rifaximin—Hypersensitivity—Capecitabine—colon cancer	0.00135	0.00135	CcSEcCtD
Rifaximin—Nervous system disorder—Methotrexate—colon cancer	0.00134	0.00134	CcSEcCtD
Rifaximin—Skin disorder—Methotrexate—colon cancer	0.00132	0.00132	CcSEcCtD
Rifaximin—Hyperhidrosis—Methotrexate—colon cancer	0.00132	0.00132	CcSEcCtD
Rifaximin—Asthenia—Capecitabine—colon cancer	0.00131	0.00131	CcSEcCtD
Rifaximin—Anorexia—Methotrexate—colon cancer	0.0013	0.0013	CcSEcCtD
Rifaximin—Pruritus—Capecitabine—colon cancer	0.0013	0.0013	CcSEcCtD
Rifaximin—Hypotension—Methotrexate—colon cancer	0.00127	0.00127	CcSEcCtD
Rifaximin—Diarrhoea—Capecitabine—colon cancer	0.00125	0.00125	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00124	0.00124	CcSEcCtD
Rifaximin—Insomnia—Methotrexate—colon cancer	0.00123	0.00123	CcSEcCtD
Rifaximin—Dyspnoea—Methotrexate—colon cancer	0.00122	0.00122	CcSEcCtD
Rifaximin—Dizziness—Capecitabine—colon cancer	0.00121	0.00121	CcSEcCtD
Rifaximin—Decreased appetite—Methotrexate—colon cancer	0.00118	0.00118	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Methotrexate—colon cancer	0.00118	0.00118	CcSEcCtD
Rifaximin—Fatigue—Methotrexate—colon cancer	0.00118	0.00118	CcSEcCtD
Rifaximin—Pain—Methotrexate—colon cancer	0.00117	0.00117	CcSEcCtD
Rifaximin—Vomiting—Capecitabine—colon cancer	0.00116	0.00116	CcSEcCtD
Rifaximin—Rash—Capecitabine—colon cancer	0.00115	0.00115	CcSEcCtD
Rifaximin—Dermatitis—Capecitabine—colon cancer	0.00115	0.00115	CcSEcCtD
Rifaximin—Headache—Capecitabine—colon cancer	0.00115	0.00115	CcSEcCtD
Rifaximin—Feeling abnormal—Methotrexate—colon cancer	0.00112	0.00112	CcSEcCtD
Rifaximin—Gastrointestinal pain—Methotrexate—colon cancer	0.00111	0.00111	CcSEcCtD
Rifaximin—Nausea—Capecitabine—colon cancer	0.00109	0.00109	CcSEcCtD
Rifaximin—Urticaria—Methotrexate—colon cancer	0.00108	0.00108	CcSEcCtD
Rifaximin—Abdominal pain—Methotrexate—colon cancer	0.00108	0.00108	CcSEcCtD
Rifaximin—Body temperature increased—Methotrexate—colon cancer	0.00108	0.00108	CcSEcCtD
Rifaximin—Hypersensitivity—Methotrexate—colon cancer	0.001	0.001	CcSEcCtD
Rifaximin—Asthenia—Methotrexate—colon cancer	0.000978	0.000978	CcSEcCtD
Rifaximin—Pruritus—Methotrexate—colon cancer	0.000964	0.000964	CcSEcCtD
Rifaximin—Diarrhoea—Methotrexate—colon cancer	0.000933	0.000933	CcSEcCtD
Rifaximin—Dizziness—Methotrexate—colon cancer	0.000901	0.000901	CcSEcCtD
Rifaximin—Vomiting—Methotrexate—colon cancer	0.000867	0.000867	CcSEcCtD
Rifaximin—Rash—Methotrexate—colon cancer	0.000859	0.000859	CcSEcCtD
Rifaximin—Dermatitis—Methotrexate—colon cancer	0.000859	0.000859	CcSEcCtD
Rifaximin—Headache—Methotrexate—colon cancer	0.000854	0.000854	CcSEcCtD
Rifaximin—Nausea—Methotrexate—colon cancer	0.00081	0.00081	CcSEcCtD
